A detailed history of Amundi transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Amundi holds 23,090 shares of IRWD stock, worth $81,507. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,090
Previous 20,709 11.5%
Holding current value
$81,507
Previous $135,000 30.37%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.93 - $7.04 $9,357 - $16,762
2,381 Added 11.5%
23,090 $94,000
Q2 2024

Aug 14, 2024

SELL
$5.58 - $8.61 $18,860 - $29,101
-3,380 Reduced 14.03%
20,709 $135,000
Q1 2024

May 15, 2024

BUY
$8.32 - $15.45 $43,239 - $80,293
5,197 Added 27.51%
24,089 $209,000
Q4 2023

Feb 14, 2024

BUY
$8.79 - $11.51 $14,063 - $18,416
1,600 Added 9.25%
18,892 $216,000
Q3 2023

Nov 14, 2023

SELL
$8.25 - $11.35 $437 - $601
-53 Reduced 0.31%
17,292 $166,000
Q2 2023

Aug 14, 2023

BUY
$10.1 - $11.6 $156,570 - $179,823
15,502 Added 841.13%
17,345 $184,000
Q4 2022

Feb 14, 2023

SELL
$9.9 - $12.43 $3.32 Million - $4.17 Million
-335,157 Reduced 99.45%
1,843 $22,000
Q3 2022

Nov 14, 2022

BUY
$10.14 - $12.38 $3.42 Million - $4.17 Million
337,000 New
337,000 $3.53 Million

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $541M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.